GCTK

GlucoTrack Inc. (GCTK) | Rumor.io

GlucoTrack

GCTK

Attention (50-day avg)0%

Attention rank (50-day avg)#948

Bullish sentiment (50-day avg)63%

Price to earnings ratio0.11

Market capitalization1.8M

Earnings per share17.3

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.4M

Social

What share of all stock conversation is about GCTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% +0	0% -0.02

Sep 25

GlucoTrack, Inc. (GCTK) expands its AI pipeline program through a collaboration with Pepperdine E2B.
The company's offering has closed, with some investors expressing hope for a bounce, while others warn of potential scams and poor financials.
GlucoTrack's stock has dropped significantly, with some investors cautioning against holding onto the shares due to a lack of fundamentals and a high float.

Generated by AI

Sentiment

Of the messages about GCTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	59.59%	60.32% -11.72	72.29% -1.14
Bearish	100% new	40.41%	39.68% +11.72	27.71% +1.14

Bullish· Sep 24

The company's recent product demonstrations and scalp treatments have generated positive biotech sentiment, fueling a nearly $3/share after-hours surge.
The stock has a strong float of only 720k shares, making it a prime candidate for a quick momentum trade with a high potential for volatility.
The company's recent reverse split has created a potential opportunity for a strong run, with the stock already breaking above previous resistance levels.

Bearish· Sep 24

The company's public offering of 1.3 million shares at $2 may have added major supply and dilution, changing the trade.
The company's previous public offering with warrants at the all-time low may have been a deliberate attempt to scam investors.
The company's stock price may be going back to $3 or lower, and investors who bought it may be leaving with losses.

Generated by AI

Topics

Of the messages about GCTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	15.62%	23.02%	43.06%
Technical Analysis	—	7.81%	7.9%	15.98%
Analysts	—	26.2%	23.7%	6.09%
Controversies	—	0%	0.23%	0.15%
Macro	—	26.2%	23.48%	29.96%
Earnings	—	24.18%	21.67%	4.77%

Announcements· Sep 24

GlucoTrack, Inc. (GCTK) has a registered direct offering of 169,388 shares at $2.04 each, with warrants to purchase up to 1,350,220 shares, aiming to raise approximately $3.1 million for debt repayment and working capital.
GlucoTrack's subsidiary Lōkahi Therapeutics has engaged two AI pipeline project teams to identify and develop overlooked GBM/brain-tumor therapies available for licensing and development, with two teams now specifically searching for such therapies.
GlucoTrack's shares surged nearly $3/share after-hours, fueled in part by attention from the “Overdrive” chat group and positive biotech sentiment following successful live product demonstrations and scalp treatments.

Technical Analysis· Jul 30

Resistance levels for $GCTK are $0.63 and $0.64, with targets at $0.68/$0.72 and extended targets at $0.90/$1.00.
A falling wedge pattern has formed, indicating a potential reversal, and the stock has already shown a strong bounce off support at $0.55.
The stock has flashed momentum signals, including a high volume breakout setup and a strengthening RSI, indicating a potential continuation of the uptrend.

Generated by AI

Community

Of the messages about GCTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	39.2%	44.69%	40.41%
Newcomers	50%	60.8%	55.31%	59.59%

Regulars· Sep 24

GlucoTrack's (GCTK) recent price action is focused on by regulars, with some discussing its potential for a short squeeze and others noting its strong gainers performance, including a 123% run after being called in a private Discord.
Regulars are monitoring GlucoTrack's (GCTK) volume and price action, with some looking for confirmation of its current trend and others planning for potential price movements, including a possible curl back to retest highs.
GlucoTrack's (GCTK) recent public offering and current cash reserves are also being discussed by regulars, who note the company's cash burn and estimated current cash, as well as its plans to engage in AI-powered pipeline project teams.

Newcomers· Sep 25

Newcomers to the GCTK asset are focused on its potential for a reversal, with some users expressing hope for a bounce or a return to previous levels.
The newcomers are also discussing the asset's fundamentals, including its expected 100%+ FY26 profit growth and the $125M Airentity deal, which some see as potential catalysts for a price increase.
There is also concern among the newcomers about the asset's potential for a collapse, with some users referencing the FDA Breakthrough designation and the risks associated with high-risk medtech stocks.

Generated by AI

News

Glucotrack announces amendments to warrant and note agreements, repays bridge notes

1d agoInvesting.com

Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

4d agoYahoo Finance

What's Going On With GlucoTrack Shares On Thursday? - GlucoTrack (NASDAQ:GCTK)

GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.

5d agoBenzinga

Glucotrack prices $3.1 million public offering at $2.04/share

5d agoInvesting.com

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

5d agoYahoo Finance

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Profusa (NASDAQ:PFSA), GlucoTrack (NASDAQ

Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. The

5d agoBenzinga

Also Discussed

Investors talking about GCTK also mention

#	Name	Attention
1	Aclarion, Inc.ACON	0%0
2	CGBS - Crown LNG Holdings Limited	——
3	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
4	Cycurion Inc.CYCU	0%0
5	Blue Hat Interactive Entertainment TechnologyBHAT	0%0
6	UOKA - MDJM Ltd	——
7	Lichen International Ltd.LICN	0%new
8	Bluejay Diagnostics Inc.BJDX	0%0
9	Webuy Global Ltd.WBUY	0%-0.02
10	TNL Mediagene Ordinary SharesTNMG	0%new

GlucoTrack Inc.

Healthcare
Medical Devices

GlucoTrack Inc. is a medical technology company focused on diabetes monitoring solutions. GlucoTrack Inc. develops devices and systems designed to measure blood glucose levels for people living with diabetes, with an emphasis on continuous monitoring and reduced reliance on traditional finger-stick testing. Its current work centers on non-invasive glucose monitoring technology and an investigational long-term implantable continuous blood glucose monitor intended for ongoing glycemic tracking. The company’s products and development programs are aimed at supporting patients with Type 1 diabetes, insulin-dependent Type 2 diabetes, and prediabetes, while also serving clinicians who manage these conditions. GlucoTrack Inc. operates within the healthcare equipment and medical device market, where glucose monitoring tools play a critical role in daily diabetes care and disease management. The company is headquartered in Rutherford, New Jersey.

Website

Location

301 Route 17 North

Rutherford, NJ, 07070

United States

Social

What share of all stock conversation is about GCTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0.01% +0.01	0% +0	0% -0.02

Sep 25

GlucoTrack, Inc. (GCTK) expands its AI pipeline program through a collaboration with Pepperdine E2B.
The company's offering has closed, with some investors expressing hope for a bounce, while others warn of potential scams and poor financials.
GlucoTrack's stock has dropped significantly, with some investors cautioning against holding onto the shares due to a lack of fundamentals and a high float.

Generated by AI

Sentiment

Of the messages about GCTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	59.59%	60.32% -11.72	72.29% -1.14
Bearish	100% new	40.41%	39.68% +11.72	27.71% +1.14

Bullish· Sep 24

The company's recent product demonstrations and scalp treatments have generated positive biotech sentiment, fueling a nearly $3/share after-hours surge.
The stock has a strong float of only 720k shares, making it a prime candidate for a quick momentum trade with a high potential for volatility.
The company's recent reverse split has created a potential opportunity for a strong run, with the stock already breaking above previous resistance levels.

Bearish· Sep 24

The company's public offering of 1.3 million shares at $2 may have added major supply and dilution, changing the trade.
The company's previous public offering with warrants at the all-time low may have been a deliberate attempt to scam investors.
The company's stock price may be going back to $3 or lower, and investors who bought it may be leaving with losses.

Generated by AI

Topics

Of the messages about GCTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	15.62%	23.02%	43.06%
Technical Analysis	—	7.81%	7.9%	15.98%
Analysts	—	26.2%	23.7%	6.09%
Controversies	—	0%	0.23%	0.15%
Macro	—	26.2%	23.48%	29.96%
Earnings	—	24.18%	21.67%	4.77%

Announcements· Sep 24

GlucoTrack, Inc. (GCTK) has a registered direct offering of 169,388 shares at $2.04 each, with warrants to purchase up to 1,350,220 shares, aiming to raise approximately $3.1 million for debt repayment and working capital.
GlucoTrack's subsidiary Lōkahi Therapeutics has engaged two AI pipeline project teams to identify and develop overlooked GBM/brain-tumor therapies available for licensing and development, with two teams now specifically searching for such therapies.
GlucoTrack's shares surged nearly $3/share after-hours, fueled in part by attention from the “Overdrive” chat group and positive biotech sentiment following successful live product demonstrations and scalp treatments.

Technical Analysis· Jul 30

Resistance levels for $GCTK are $0.63 and $0.64, with targets at $0.68/$0.72 and extended targets at $0.90/$1.00.
A falling wedge pattern has formed, indicating a potential reversal, and the stock has already shown a strong bounce off support at $0.55.
The stock has flashed momentum signals, including a high volume breakout setup and a strengthening RSI, indicating a potential continuation of the uptrend.

Generated by AI

Community

Of the messages about GCTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	50%	39.2%	44.69%	40.41%
Newcomers	50%	60.8%	55.31%	59.59%

Regulars· Sep 24

GlucoTrack's (GCTK) recent price action is focused on by regulars, with some discussing its potential for a short squeeze and others noting its strong gainers performance, including a 123% run after being called in a private Discord.
Regulars are monitoring GlucoTrack's (GCTK) volume and price action, with some looking for confirmation of its current trend and others planning for potential price movements, including a possible curl back to retest highs.
GlucoTrack's (GCTK) recent public offering and current cash reserves are also being discussed by regulars, who note the company's cash burn and estimated current cash, as well as its plans to engage in AI-powered pipeline project teams.

Newcomers· Sep 25

Newcomers to the GCTK asset are focused on its potential for a reversal, with some users expressing hope for a bounce or a return to previous levels.
The newcomers are also discussing the asset's fundamentals, including its expected 100%+ FY26 profit growth and the $125M Airentity deal, which some see as potential catalysts for a price increase.
There is also concern among the newcomers about the asset's potential for a collapse, with some users referencing the FDA Breakthrough designation and the risks associated with high-risk medtech stocks.

Generated by AI

GlucoTrack

Social

Sep 25

Bullish· Sep 24

Bearish· Sep 24

Announcements· Sep 24

Technical Analysis· Jul 30

Regulars· Sep 24

Newcomers· Sep 25

Glucotrack announces amendments to warrant and note agreements, repays bridge notes

Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

What's Going On With GlucoTrack Shares On Thursday? - GlucoTrack (NASDAQ:GCTK)

Glucotrack prices $3.1 million public offering at $2.04/share

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Profusa (NASDAQ:PFSA), GlucoTrack (NASDAQ

Also Discussed

GlucoTrack Inc.

Company Information

Location

Glucotrack announces amendments to warrant and note agreements, repays bridge notes

Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

What's Going On With GlucoTrack Shares On Thursday? - GlucoTrack (NASDAQ:GCTK)

Glucotrack prices $3.1 million public offering at $2.04/share

Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Profusa (NASDAQ:PFSA), GlucoTrack (NASDAQ

Also Discussed

Social

Sep 25

Bullish· Sep 24

Bearish· Sep 24

Announcements· Sep 24

Technical Analysis· Jul 30

Regulars· Sep 24

Newcomers· Sep 25